AMAM logo

Ambrx Biopharma (AMAM) EBITDA

Annual EBITDA

-$73.29 M
-$7.16 M-10.82%

December 31, 2022

Summary

Performance

1-Year Change

-10.82%

3-Year Change

-258.92%

5-Year Change

-258.92%

15-Year Change

-258.92%

AMAM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$11.17 M

3-Year Low

-$73.29 M
AMAM annual EBITDA is currently at its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2022
AMAM previous annual earnings announcement was published on Dec 31, 2022

Next Annual Earnings Report Date

N/A
AMAM next annual earnings announcement has not yet been scheduled

OtherAMAMprofitabilitymetrics:

Annual Revenue

$7.40 M
AMAM annual revenue is $7.40 million

Annual Net Income

-$78.00 M
AMAM annual net profit is -$78.00 million

Annual EBIT

-$75.09 M
AMAM annual earnings before interest & taxes is -$75.09 million

Annual EPS

-$0.29
AMAM annual earnings per share is -$0.29

Quarterly EBITDA

-$25.25 M
-$6.44 M-34.27%

September 1, 2023

Summary

Performance

3-Month Change

-34.27%

1-Year Change

-65.78%

3-Year Change

-

5-Year Change

-

AMAM Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$10.35 M

3-Year Low

-$25.25 M
AMAM quarterly EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2023
AMAM previous earnings announcement was published on Sep 1, 2023

Next Quarterly Earnings Report Date

N/A
AMAM next earnings announcement has not yet been scheduled

OtherAMAMprofitabilitymetrics:

Quarterly Revenue

$53.00 K
AMAM quarterly revenue is $53.00 thousand

Quarterly Net Income

-$22.99 M
AMAM quarterly net profit is -$22.99 million

Quarterly EBIT

-$25.63 M
AMAM quarterly earnings before interest & taxes is -$25.63 million

Quarterly EPS

-$0.37
AMAM quarterly earnings per share is -$0.37

TTM EBITDA

-$70.07 M
-$10.02 M-16.68%

September 1, 2023

Summary

Performance

3-Month Change

-16.68%

1-Year Change

-31.28%

3-Year Change

-

5-Year Change

-

AMAM TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

-$17.10 M

3-Year Low

-$70.07 M
AMAM TTM EBITDA is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 1, 2023
AMAM previous earnings announcement was published on Sep 1, 2023

Next Quarterly Earnings Report Date

N/A
AMAM next earnings announcement has not yet been scheduled

OtherAMAMprofitabilitymetrics:

TTM Revenue

$4.09 M
AMAM TTM revenue is $4.09 million

TTM Net Income

-$67.06 M
AMAM TTM net profit is -$67.06 million

TTM EBIT

-$71.55 M
AMAM TTM earnings before interest & taxes is -$71.55 million

TTM EPS

-$0.51
AMAM TTM earnings per share is -$0.51

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$73.29 M
AMAM annual EBITDA is -$73.29 million

Annual Net Income

-$78.00 M
AMAM annual net profit is -$78.00 million

Annual Interest Expense

$968.00 K
AMAM annual interest expense is $968.00 thousand

Annual Income Tax

$1.94 M
AMAM annual income tax is $1.94 million

Annual D&A

$1.80 M
AMAM annual depreciation & amortization is $1.80 million

AMAM EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-10.8%-65.8%-31.3%
3 y3 years-258.9%--
5 y5 years-258.9%--

AMAM EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year+10.8%at low+143.8%at low+309.7%at low
5 y5-year+556.0%at low+143.8%at low+309.7%at low
alltimeall time+556.0%at low+143.8%at low+309.7%at low

Ambrx Biopharma EBITDA History

DateAnnualQuarterlyTTM
Sep 2023
-
-$25.25 M(+34.3%)
-$70.07 M(+16.7%)
Jun 2023
-
-$18.80 M(+20.0%)
-$60.05 M(-3.6%)
Mar 2023
-
-$15.67 M(+51.3%)
-$62.29 M(-2.3%)
Dec 2022
-$73.29 M
-$10.35 M(-32.0%)
-$63.73 M(+19.4%)
Sep 2022
-
-$15.23 M(-27.6%)
-$53.37 M(+39.9%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$21.04 M(+23.0%)
-$38.15 M(+123.0%)
Mar 2022
-
-$17.10 M
-$17.10 M
Dec 2021
-$66.13 M(+492.0%)
-
-
Dec 2020
-$11.17 M(-45.3%)
-
-
Dec 2019
-$20.42 M
-
-

FAQ

  • What is Ambrx Biopharma annual EBITDA?
  • What is the all time high annual EBITDA for Ambrx Biopharma?
  • What is Ambrx Biopharma annual EBITDA year-on-year change?
  • What is Ambrx Biopharma quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Ambrx Biopharma?
  • What is Ambrx Biopharma quarterly EBITDA year-on-year change?
  • What is Ambrx Biopharma TTM EBITDA?
  • What is the all time high TTM EBITDA for Ambrx Biopharma?
  • What is Ambrx Biopharma TTM EBITDA year-on-year change?

What is Ambrx Biopharma annual EBITDA?

The current annual EBITDA of AMAM is -$73.29 M

What is the all time high annual EBITDA for Ambrx Biopharma?

Ambrx Biopharma all-time high annual EBITDA is -$11.17 M

What is Ambrx Biopharma annual EBITDA year-on-year change?

Over the past year, AMAM annual EBITDA has changed by -$7.16 M (-10.82%)

What is Ambrx Biopharma quarterly EBITDA?

The current quarterly EBITDA of AMAM is -$25.25 M

What is the all time high quarterly EBITDA for Ambrx Biopharma?

Ambrx Biopharma all-time high quarterly EBITDA is -$10.35 M

What is Ambrx Biopharma quarterly EBITDA year-on-year change?

Over the past year, AMAM quarterly EBITDA has changed by -$10.02 M (-65.78%)

What is Ambrx Biopharma TTM EBITDA?

The current TTM EBITDA of AMAM is -$70.07 M

What is the all time high TTM EBITDA for Ambrx Biopharma?

Ambrx Biopharma all-time high TTM EBITDA is -$17.10 M

What is Ambrx Biopharma TTM EBITDA year-on-year change?

Over the past year, AMAM TTM EBITDA has changed by -$16.70 M (-31.28%)